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Introduction: Obstructive sleep apnea (OSA) causes endothelial dysfunction and is an
independent risk factor for hypertension and cardiovascular diseases. Although vasoactive
agents and sympathoexcitation have been implicated and operational in the pathogenesis of
hypertension associated with OSA the exact mechanisms underlying hypertension have not
been established. Soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng) are
released under hypoxic stress and cause endothelial dysfunction and hypertension in humans
and animals. The present study was conducted to investigate the role of these antiangiogenic
proteins in OSA and to determine their clinical significance.
Methods: In 22 untreated OSA patients with apnea-hypopnea index 30 events/h (11 with
hypertension and 11 without hypertension) we measured plasma concentrations of endothe-
lin-1, epinephrine, norepinephrine, nitric oxide metabolites, sFlt-1 and sEng.
Results: The apnea-hypopnea indices were 81  11 and 76  9 events/h (PZ ns) and the sleep
times with SaO2< 90% were 42  13 and 39  13 min (PZ ns) for normotensives and hyperten-
sives, respectively. Both groups had similarly elevated levels of catecholamines with normal
endothelin-1 levels. Nitric oxide metabolites were depressed in both groups with no inter-
group differences. On the other hand, both sFlt-1 (90.0  4.6 pg/ml vs. 74.0  4.4 pg/ml,
PZ 0. 018) and sEng (4.9  0.34 ng/ml vs. 3.50  0.42 ng/ml, PZ 0.016) were significantly
elevated in the hypertensive patients compared to the normotensive subjects.
Conclusion: These data show that sFlt-1 and sEng are increased in the circulation of patients
with OSA and hypertension and suggest that they may be involved in the pathogenesis of
hypertension.
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Obstructive sleep apnea syndrome (OSA) is a common
disorder affecting 2e4% of the general population.1,2 The
OSA syndrome is characterized by repetitive closure of the
upper airway during sleep and is often associated with sleep
fragmentation, sleepiness and hypoxemia. OSA increases
the risk of hypertension, coronary artery disease, stroke
and death.3e8 The acute hemodynamic and autonomic
perturbations that accompany obstructive apneas during
sleep, with associated arousals and intermittent hypox-
emia, can lead to sustained daytime hypertension.5,9 The
underlying mechanisms mediating this association or
causation are incompletely understood. Circulating vaso-
active factors, such as endothelin-1, catecholamines,
angiotensin and aldosterone have been implicated in the
pathogenesis of hypertension in OSA10e14 but the findings
have been inconsistent across studies.15e20 Moreover, not
all patients with OSA have or develop hypertension21e23 nor
there is correlation between hypertension and these
potential pathogenetic factors.11
Current evidence suggests that inflammatory processes,
oxidative stress and endothelial dysfunction play pivotal
roles in the pathogenesis of hypertension and vascular
complications in OSA.24 Circulating soluble fms-like tyrosine
kinase-1 (sFlt-1, also referred to as sVEGFR-1) and soluble
endoglin (sEng) are antiangiogenic proteins that are
released under hypoxic stress and inflammatory state.25,26
These circulating proteins have been shown to have path-
ogenetic roles in endothelial dysfunction and hypertension
in preeclampsia,27 in human chronic kidney disease,28
acute myocardial infarction29 and in animal models of
hypertension.30e32
Serum sFlt-1 and sEng levels have not been determined
in patients with OSA. Since a large proportion of these
patients have hypertension, we hypothesized that sFlt-1
and sEng levels are increased in those patients with
hypertension, providing some insight into the pathogenesis
of hypertension and potentially constituting novel cardio-
vascular risk factors in OSA.
Methods
Subjects
Patients with newly diagnosed severe obstructive sleep
apnea (apnea-hypopnea index, AHI 30 events/h) were
sequentially recruited from the Yale Center for Sleep
Medicine. This category of patients with OSA is particularly
at increased risk of hypertension.5 Hypertension was
defined by blood pressure 149/90 mm Hg, which had been
previously diagnosed according to the criteria set forth by
the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure.33 In
addition, in the morning of the study day and after 30 min
of rest blood pressure was measured in seated position
three times every 5 min using an appropriately-sized arm
cuff and a calibrated aneroid manometer according to
the standard methods.33 Subjects were excluded if they
had known coronary artery disease, vascular disease,
chronic kidney disease, or cancer based on a standardizedquestionnaire and information obtained from their physi-
cians. None of the subjects had received treatment for
their OSA prior to the study. Subjects refrained from having
any caffeine-containing beverages or smoking within 6 h of
the study.
Assessment of sleep and sleep-disordered
breathing
Baseline nocturnal polysomnography was performed within
one week prior to the study day for all subjects using
a computerized Grass data acquisition system (Astro-Med,
Inc. West Warwick, RI) as previously described.34 Sleep
state was recorded with four channels of electro-enceph-
alogram (C3/A2, C4/A1, O2/A1, O1/A2), two channels of
electro-oculogram, and one-channel submental electro-
myogram. Breathing was assessed by monitoring chest and
abdominal movements with piezo-pneumographs, and nasal
and oral airflow using pressure transducers and thermisters,
respectively. Arterial oxygen saturation was measured using
a pulse oximeter. Leg movements were recorded with two
channels of electromyogram and electrocardiogram was
monitored continuously for heart rate. Apnea was defined
as at least an 80% reduction in airflow for 10 s. Obstructive
sleep apnea was defined when respiratory efforts were
present and central apnea when respiratory efforts were
absent. Hypopnea was scored when there was 30%e80%
decrease in airflow signal with a 4% decrease in oxygen
saturation.35
Blood sample
A venous blood sample was obtained in the morning after the
subjects had been seated and rested for 30 min. Plasma was
separated with centrifugation at 1000 g for 15 min. After
centrifugation, plasma was aliquoted and stored at 80 C
for subsequent batch analysis. We used plasma instead of
serum to avoid the possible release of the vasoactive factors
from circulating cells. Each subject was informed of the
experimental procedures and signed the consent form
approved by the Human Investigation Committee of Yale
University School of Medicine.
Measurement of norepinephrine and epinephrine
Plasma concentrations of norepinephrine and epinephrine
were measured by high performance liquid chromatog-
raphy.36 With this method, catecholamines undergo initial
extraction and purification by absorption to silica powder,
followed by HPLC column separation and electrochemical
detection (ESA, Chelmsford, MA, USA). The method enables
the detection of catecholamine levels of 5 pg/ml with
a mean coefficient of variation of values obtained from the
same sample of 4%.
Measurement of endothelin-1
Concentrations of endothelin-1 in plasma were measured
using an ELISA kit according to the manufacture’s protocol
(ALPCO Diagnostics, Salem, NH, USA). The detection limit
of this assay was 0.05 pg/ml.
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The plasma levels of more stable metabolites of NO, nitrite
(NO2
) and nitrate (NO3
) were measured according to Griess
Reaction (R & D Systems, Minneapolis, MN, USA). Nitrate is
converted to nitrite by nitrate reductase. The reaction is fol-
lowedby colorimetric detectionofnitrite as anazodyecoupled
to N-(1-naphthyl)ethylenediamine to form the chromophoric
azo-derivative which absorbs light at 650-570 nm.37 The
minimum detectable level ranges from 0.09 to 0.78 mmol/L.
The inter- and intra-assay coefficient of variation was <4.6%.
Measurement of plasma soluble Flt-1 and soluble
endoglin
Circulating levels of sFlt-1 and sEng in plasma were
measured using ELISA method according to a protocol by R
& D Systems (Minneapolis, MN, USA). All samples were
assayed in duplicate. Standards and control samples were
run simultaneously for validation. The minimum detection
limits for sFlt-1 and sEng were 3.5 pg/ml and 0.007 ng/ml,
respectively. Inter- and intra-assay coefficient of variations
for both assays were <10%.
Data analysis
Data are expressed as mean SE. Data were analyzed using
unpaired two-tailed Student t test (Graphpad Prism, La
Jolla, CA). Z-test was used for comparing proportions
(Systat Software, Richmond, CA). A P< 0.05 was considered
statistically significant.
Results
Subjects characteristics
We consecutively screened 75 patients who had undergone
polysomnography and had been diagnosed with OSA. Fifty-Table 1 Patient characteristics.
Normotensive
Age 48 4
Sex, M/F 10/1
Race, White, % 100
BMI 41 4
Co-morbidities
Diabetes mellitus, % 11
Hyperlipidemia, % 40
Systolic BP, mmHg 121 4
Diastolic BP, mmHg 78 3
Apnea-Hypopnea Index, events/hr 81 11
Mean SaO2, awake, % 94 1
Mean SaO2, asleep, % 91 0.6
Nadir SaO2, asleep, % 77 3
SaO2< 90% during sleep, min 42 13
Oxygen Desaturation Index >4%/h 45 7
Arousal index 77 12
Data are Means SE.three patients were excluded because of history of coronary
artery disease, peripheral vascular disease, chronic kidney
disease, stroke, cancer, had received treatment for OSA or
had AHI < 30/h. Twenty-two subjects with newly diagnosed
severe OSA who had not yet received treatment for their
sleep breathing disorder comprised the study population
(Table 1). Subjects were all obese with no statistically
significant differences in BMI and age between the two
groups. The z-statistic showed no significant differences
with respect to co-morbidities and use of medications (sta-
tins and oral hypoglycemics). There were 2 smokers (less
than one pack per day) in the hypertensive group and none
in the normotensive group. Subjects with hypertension were
on either ACE inhibitors or diuretics or both. The subjects
were stratified according to the presence or absence of
hypertension and were otherwise fully matched for the
severity of obesity, sleep apnea and oxygen desaturation
indices. There were 11 subjects without hypertension (age
48  4 yr) and 11 with hypertension (age 45  2 yr). All
subjects had markedly elevated AHI and significant oxygen
desaturations during sleep. The time spent during sleep with
oxygen saturation (SaO2) <90% (T < 90) were 42  13 min
and 39  13 min (PZ ns) and the nadir asleep SaO2 were
77%  3 and 79%  2 (PZ ns) in normotensive and hyper-
tensive subjects, respectively.
Circulating vasoactive factors
Norepinephrine and epinephrine concentrations were
elevated in both normotensive (790  110 pg/ml;
54.0  11.0 pg/ml, respectively) and hypertensive OSA
patients (840  92 pg/ml; 38  5.9 pg/ml, respectively)
with no statistically significant difference between the two
groups.38,39 In our study the morning plasma ET-1 concen-
trations in normotensive (1.40  0.33 pg/ml) and hyper-
tensive patients (0.73  0.09 pg/ml) were not elevated.
Total nitrite and nitrate levels were decreased, 30 11 mM
and 39  13 mM in normotensive and hypertensive subjects,
respectively with no significant inter-group difference.OSA Hypertensive OSA P-value
45 2 ns
10/1 ns
100 ns
40 2 ns
15 ns
10 ns
135 3 <0.02
88 2 <0.04
76 9 ns
95 0.4 ns
91 0.5 ns
79 2 ns
39 13 ns
50 9 ns
71 9 ns
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the hypertensive subjects compared with the normotensive
group (90.0  4.6 pg/ml vs. 74.0  4.4 pg/ml, PZ 0.018)
(Fig. 1). Similarly, plasma levels of sEng were significantly
elevated in the hypertensive subjects (4.90  0.34 ng/ml)
compared with the normotensive subjects (3.50  0.42 ng/
ml), PZ 0.016.Discussion
The aim of this study was to investigate circulating sFlt-1 and
sEng inOSA and their clinical significance in hypertension.We
have shown that patients with OSA and hypertension have
higher levels of these proteins than their normotensive
counterparts. The two groups were otherwise comparable in
respect to BMI, AHI, oxygen desaturation indices (nadir SaO2
and T < 90) and arousal index. Although the plasma
concentrations of catecholamines were elevated in both
groups, an increase of 3.6-fold and 3.3-fold in norepinephrine
levels and 1.3-fold and1.8-fold in epinephrine concentrations
in hypertensive and normotensive patients, respectively,38,39
there were no significant inter-group differences. ET-1 levels
were comparable to the normative data on morning plasma
ET-1 concentrations of healthy controls, 0.81 0.05 pg/ml16
and with no significant difference between the two groups.
Our results on plasma concentrations of catecholamines and
ET-1 are similar to those of previous studies and indicate the
adequacy of the sample size and the representative pop-
ulation of OSA patients.11,16 The data on depressed plasma
NO metabolites in the entire cohort are in accord with prior
studies and consistent with current paradigm of increased
oxidative stress in OSA.40,41 The decrease in NO metabolites
in both normotensive and hypertensive patients suggests
potential perturbation in endothelial function but would not
explain the presence of hypertension.41 Therefore, the lack
of differences in catecholamines, ET-1 and NO metabolites
between the two groups suggests that additionalmechanisms
are involved in the pathogenesis of hypertension in OSA.
Intermittent hypoxia causes systemic hypertension in
laboratory animals that lasts beyond theexposureperiod.42,43
In humans, OSA is associated with systemic endothelial
dysfunction, hypertension, inflammation, and oxidative
stress.24,27 Oxidative stress is an inflammatory stimulus
mediated by reactive oxygen species. Hypoxia, oxidative
stress and pro-inflammatory state are thought to provoke the
release of sFlt-1 and sEng via hypoxia-inducible factor-1a
(HIF-1a) and NF-lB signaling pathways.25,26 VEGF, a potentFigure 1 Circulating plasma levels of sFlt-1 and sEndoglin in nor
levels in the hypertensive group (unpaired two-tailed Student t teangiogenic protein, promotes vasodilatation by inducing
nitric oxide and prostacyclin synthesis in endothelial cells.
Plasma levels of VEGF are similar in normotensive patients
with OSA and age- and BMI-matched controls, whereas
hypertensive patients with OSA have higher VEGF levels.44
Membrane-bound Flt-1, an fms-like tyrosine kinase-1, is
a receptor for VEGF. sFlt-1 is a circulating splice variant with
antagonist activity for VEGF. While sFlt-1 is not a vasocon-
strictor, it does significantly inhibit the dilatory actions of
VEGF in vitro, and chronic elevations in circulating concen-
trations result in increased blood pressure.31,32 Blocking VEGF
with bevacizumab, an anti-VEGF antibody, results in hyper-
tension in high percentage of patients receiving this treat-
ment.45 Furthermore, over-expression of sFlt-1 in rats leads
to hypertension and proteinuria30 Conversely, reduction of
sFlt-1 alleviates hypertension.46 The circulating levels of sFlt-
1 in hypertensive subjects in our study are similar to those
patients with moderate chronic kidney disease with
endothelial dysfunction.28 In the latter study, not only sFlt-1
levels were elevated and positively correlated with plasma
vWF and sVCAM-1 levels, both markers of endothelial
dysfunction, but even more important it correlated with the
Framingham risk score for cardiovascular disease.28 The
increased circulating levels of sFlt-1 in our study is likely
secondary to OSA rather that hypertension being the cause of
sFlt-1 release since otherwise healthy patients with hyper-
tension do not have elevated levels of this protein.28 Further
support for this hypothesis is the elevated plasma VEGF
concentrations in hypertensive OSA subjects44 presumably in
response to sFlt-1.
Endoglin is expressed in vascular endothelial and smooth
muscle cells as an auxiliary receptor to TGF-b and plays an
important role in the homeostasis of vascular function.47
Vascular injury results in increased endoglin expression in
endothelial cells.48 Transcriptional activation of endoglin
and TGF-b signaling components by cooperative interaction
suggests that these factors play a significant role in the
response to vascular injury.48 Circulating sEng is a trun-
cated form of endoglin, which binds and antagonizes TGF-
b. sEng amplifies the vascular damage mediated by sFlt-1.49
Both the release of sFlt-1 and sEng, in concert, results in
decreased prostacyclin and nitric oxide production, release
of procoagulant proteins, endothelial cell dysfunction and
hypertension.49,50 Since both sFlt-1 and sEng are highly
expressed in human peripheral blood monocytes51 and
endothelial cells,52 respectively, and are released under
oxidative stress and pro-inflammatory state we propose
that these proteins may play a role in the pathogenesis ofmotensive and hypertensive patients with OSA showing higher
st).
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patients with OSA are necessarily at high risk for hyper-
tension.21e23 This suggests that among patients with OSA
there are different biological responses to intermittent
hypoxia and oxidative stress that result in increased
susceptibility not only to development of hypertension but
also to other vascular diseases in only a subpopulation of
these patients.3e8,21 The exact mechanisms for generation
of sFlt-1 and sEng are not established. We speculate that
there may be differences in HIF-1a and NF-lB signaling
pathways promoting generation of these antiangiogenic
factors between those with hypertension and OSA and their
normotensive counterparts. Alternatively, but not exclu-
sively, there may be differential splicing of sFlt-1 and sEng
in response to oxidative stress in only a subgroup that
develops hypertension.
Limitations of the study
There are some potential limitations to this study. Some of
the patients were on antihypertensive medications, which
could have influenced the results, but there is no evidence
that ACE inhibitors or diuretics have any effects on these
circulating proteins.53 Statins are known to increase sFlt-1
levels in patients with acute myocardial infarction;
however, it is unlikely that this had influenced the results
since both groups were on statins.
In summary, we have demonstrated an increase in
circulating concentrations of sFlt-1 and sEng, two anti-
angiogenic proteins with antagonistic properties against
VEGF and TGF-b signaling, in patients with OSA and hyper-
tension. Other vasoactive factors such as endothelin-1 and
catecholamines were not significantly different between
hypertensive and normotensive. Although hypertension is
a complex trait and the development of hypertension in OSA
patients is likely multifactorial, we believe that our results
indicate that these antiangiogenic proteins, which are
produced under intermittent hypoxia, oxidant stress and
inflammatory state, are potentially involved in the patho-
physiology of hypertension in these patients. In addition,
our data provide potential avenues for further investigation
into the mechanism of individual differences in biological
propensity for the development of hypertension in this
setting. Further studies are needed to investigate the
mechanisms of regulation of these antiangiogenic proteins
in OSA and for better understanding of the pathophysiology
of hypertension in these patients.Acknowledgement
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